Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1996 2
1997 2
1998 1
1999 2
2000 2
2002 4
2003 6
2004 4
2005 3
2006 6
2007 9
2008 9
2009 9
2010 11
2011 14
2012 13
2013 15
2014 10
2015 22
2016 23
2017 23
2018 16
2019 16
2020 15
Text availability
Article attribute
Article type
Publication date

Search Results

202 results
Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Depression and suicidality in psoriasis: review of the literature including the cytokine theory of depression.
Koo J, Marangell LB, Nakamura M, Armstrong A, Jeon C, Bhutani T, Wu JJ. Koo J, et al. J Eur Acad Dermatol Venereol. 2017 Dec;31(12):1999-2009. doi: 10.1111/jdv.14460. Epub 2017 Aug 9. J Eur Acad Dermatol Venereol. 2017. PMID: 28681405 Review.
Proinflammatory cytokines such as interleukin (IL)-1 and IL-6 are elevated in both psoriasis and depression, indicating that the inflammatory process may be involved in the progression of both diseases. ...Additionally, we review the most prominent hypotheses
Proinflammatory cytokines such as interleukin (IL)-1 and IL-6 are elevated in both psoriasis and depression, indicating
Proinflammatory cytokine responses in patients with psoriasis.
Kouris A, Pistiki A, Katoulis A, Georgitsi M, Giatrakou S, Papadavid E, Netea MG, Stavrianeas N, Giamarellos-Bourboulis EJ. Kouris A, et al. Eur Cytokine Netw. 2014 Oct-Dec;25(4):63-8. doi: 10.1684/ecn.2014.0358. Eur Cytokine Netw. 2014. PMID: 25679113 Free article.
BACKGROUND: Psoriasis is one of the most common, immune-mediated, chronic inflammatory skin diseases. Proinflammatory cytokines play an important pathogenetic role at a local level. OBJECTIVE: To assess whether the proinflammatory cytokines IL-1 …
BACKGROUND: Psoriasis is one of the most common, immune-mediated, chronic inflammatory skin diseases. Proinflammatory cytok
β-Defensin 2 is a responsive biomarker of IL-17A-driven skin pathology in patients with psoriasis.
Kolbinger F, Loesche C, Valentin MA, Jiang X, Cheng Y, Jarvis P, Peters T, Calonder C, Bruin G, Polus F, Aigner B, Lee DM, Bodenlenz M, Sinner F, Pieber TR, Patel DD. Kolbinger F, et al. J Allergy Clin Immunol. 2017 Mar;139(3):923-932.e8. doi: 10.1016/j.jaci.2016.06.038. Epub 2016 Aug 5. J Allergy Clin Immunol. 2017. PMID: 27502297 Free article.
Proteomic and gene transcription analyses revealed dysregulated antimicrobial peptides, proinflammatory cytokines, and neutrophil chemoattractants, levels of which returned to normal after treatment with secukinumab. β-Defensin 2 (BD-2) was identified as a biomarker …
Proteomic and gene transcription analyses revealed dysregulated antimicrobial peptides, proinflammatory cytokines, and neutrop …
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.
Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, Cameron GS, Erickson J, Zhang L, Secrest RJ, Ball S, Braun DK, Osuntokun OO, Heffernan MP, Nickoloff BJ, Papp K; UNCOVER-2 and UNCOVER-3 investigators. Griffiths CE, et al. Lancet. 2015 Aug 8;386(9993):541-51. doi: 10.1016/S0140-6736(15)60125-8. Epub 2015 Jun 10. Lancet. 2015. PMID: 26072109 Clinical Trial.
BACKGROUND: Ixekizumab is a humanised monoclonal antibody against the proinflammatory cytokine interleukin 17A. We report two studies of ixekizumab compared with placebo or etanercept to assess the safety and efficacy of specifically targeting interleukin 17A in …
BACKGROUND: Ixekizumab is a humanised monoclonal antibody against the proinflammatory cytokine interleukin 17A. We report two …
Proinflammatory and anti-inflammatory cytokine profiles in psoriasis: use as laboratory biomarkers and disease predictors.
Cataldi C, Mari NL, Lozovoy MAB, Martins LMM, Reiche EMV, Maes M, Dichi I, Simão ANC. Cataldi C, et al. Inflamm Res. 2019 Jul;68(7):557-567. doi: 10.1007/s00011-019-01238-8. Epub 2019 May 6. Inflamm Res. 2019. PMID: 31062065
SUBJECTS AND METHODS: This study recruited 70 patients with psoriasis and 76 healthy controls. Cytokine profiles were evaluated, including pro-inflammatory M1 (IL-1 + IL-6 + TNF-α), Th1 (IL-2 + IL-12 + IFN-γ), Th17 (IL-6 + IL-17), and immune-inflammatory r
SUBJECTS AND METHODS: This study recruited 70 patients with psoriasis and 76 healthy controls. Cytokine profiles were e …
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.
McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, van der Heijde D, Landewé R, Conaghan PG, Gottlieb AB, Richards H, Pricop L, Ligozio G, Patekar M, Mpofu S; FUTURE 2 Study Group. McInnes IB, et al. Lancet. 2015 Sep 19;386(9999):1137-46. doi: 10.1016/S0140-6736(15)61134-5. Epub 2015 Jun 28. Lancet. 2015. PMID: 26135703 Clinical Trial.
BACKGROUND: Interleukin 17A is a proinflammatory cytokine that is implicated in the pathogenesis of psoriatic arthritis. We assessed the efficacy and safety of subcutaneous secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoria …
BACKGROUND: Interleukin 17A is a proinflammatory cytokine that is implicated in the pathogenesis of psoriatic arthritis. We as …
Biomarkers of Inflammation in Obesity-Psoriatic Patients.
Rodríguez-Cerdeira C, Cordeiro-Rodríguez M, Carnero-Gregorio M, López-Barcenas A, Martínez-Herrera E, Fabbrocini G, Sinani A, Arenas-Guzmán R, González-Cespón JL. Rodríguez-Cerdeira C, et al. Mediators Inflamm. 2019 May 28;2019:7353420. doi: 10.1155/2019/7353420. eCollection 2019. Mediators Inflamm. 2019. PMID: 31275060 Free PMC article. Review.
In addition, the severity of psoriasis seems to be related to the severity of obesity. Patients with higher levels of obesity show poorer response to systemic treatments of psoriasis. ...These results strongly suggest that obesity, through proinflam
In addition, the severity of psoriasis seems to be related to the severity of obesity. Patients with higher levels of obesity …
Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease.
Scher JU, Ubeda C, Artacho A, Attur M, Isaac S, Reddy SM, Marmon S, Neimann A, Brusca S, Patel T, Manasson J, Pamer EG, Littman DR, Abramson SB. Scher JU, et al. Arthritis Rheumatol. 2015 Jan;67(1):128-39. doi: 10.1002/art.38892. Arthritis Rheumatol. 2015. PMID: 25319745 Free PMC article.
CONCLUSION: Patients with PsA and patients with skin psoriasis had a lower relative abundance of multiple intestinal bacteria. ...Thus, the role of the gut microbiome in the continuum of psoriasis-PsA pathogenesis and the associated immune response
CONCLUSION: Patients with PsA and patients with skin psoriasis had a lower relative abundance of multiple intestinal ba …
Gain-of-Function Mutation of Card14 Leads to Spontaneous Psoriasis-like Skin Inflammation through Enhanced Keratinocyte Response to IL-17A.
Wang M, Zhang S, Zheng G, Huang J, Songyang Z, Zhao X, Lin X. Wang M, et al. Immunity. 2018 Jul 17;49(1):66-79.e5. doi: 10.1016/j.immuni.2018.05.012. Epub 2018 Jul 3. Immunity. 2018. PMID: 29980436 Free article.
Genetic mutations of CARD14 (encoding CARMA2) are observed in psoriasis patients. Here we showed that Card14(E138A/+) and Card14(ΔQ136/+) mice developed spontaneous psoriasis-like skin inflammation, which resulted from constitutively activated CARMA2 via self …
Genetic mutations of CARD14 (encoding CARMA2) are observed in psoriasis patients. Here we showed that Card14(E138A/+) and Card …
IκBζ is a key transcriptional regulator of IL-36-driven psoriasis-related gene expression in keratinocytes.
Müller A, Hennig A, Lorscheid S, Grondona P, Schulze-Osthoff K, Hailfinger S, Kramer D. Müller A, et al. Proc Natl Acad Sci U S A. 2018 Oct 2;115(40):10088-10093. doi: 10.1073/pnas.1801377115. Epub 2018 Sep 17. Proc Natl Acad Sci U S A. 2018. PMID: 30224457 Free PMC article.
Although IL-17A and TNFα are effective therapeutic targets in psoriasis, IL-36 has recently emerged as a proinflammatory cytokine. ...Moreover, expression of IκBζ mRNA was highly up-regulated in biopsies of psoriasis patients where it coincided …
Although IL-17A and TNFα are effective therapeutic targets in psoriasis, IL-36 has recently emerged as a proinflammatory cy
202 results
Jump to page
Feedback